Navigation Links
ExonHit Therapeutics Expands Strategic Collaboration With Allergan
Date:1/6/2009

PARIS, France, January 6 /PRNewswire-FirstCall/ --

- Early Renewal of the Agreement to Extend the Collaboration Until December 2011

- Expansion of the Scope of the Collaboration to Include Antibody Discovery in Ophthalmology

- Revised Commercial Terms and Payments to ExonHit if Allergan Sublicenses to a Third Party

ExonHit Therapeutics (Alternext: ALEHT) today announced a reinforcement of its existing drug discovery collaboration with Allergan Sales, LLC (NYSE: AGN). The collaboration is extended until December 2011, includes antibody discovery within the scope of the research activities and encompasses revised commercial terms.

The collaboration which has been renewed several times and initiated in December 2002 focuses on the identification, development and commercialization of drugs for the treatment of neurodegenerative diseases, pain and ophthalmology. EHT/AGN 0001, the most advanced compound out of the collaboration, is currently ending Phase I clinical trials for pain indications. EHT/AGN 0002 and other compounds are in pre-clinical testing for indications in pain, ophthalmology or neurodegenerative diseases.

Allergan exercised its option to extend this collaboration until December 2011 earlier than anticipated. As part of the renewal agreement, Allergan will provide ExonHit with increased quarterly research funding instead of a single payment.

The scope of the collaboration is expanded to include epitope* discovery for the development of antibody therapeutics in ocular disorders. ExonHit's unique gene profiling technology can readily be applied to identify disease specific target proteins, but also pinpoints novel epitopes present in those proteins, which are produced via alternative splicing. ExonHit's approach offers the potential be
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
2. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
3. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
4. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
5. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
6. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
9. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
10. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
11. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Conn., Sept. 21 In a platform presentation at ... the Study of Diabetes (EASD) in Stockholm, investigators for ... the results of a clinical study evaluating a new ... (Profil Institute for Metabolic Research, Neuss, Germany) and colleagues ...
... Inc. (Nasdaq: VVUS ) today announced positive ... Controlled Release Capsules, an investigational therapy for treatment of ... Americans. The findings come from the ... subset of patients who completed the previously reported 56-week ...
Cached Medicine Technology:Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 2Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 2New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 4New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 5New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 6
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... TORONTO, April 24, 2014 Pregnant immigrants from ... require increased monitoring during pregnancy, according to new ... published today in the British Journal of ... preeclampsia and eclampsia rates among immigrants and native-born ... Canada (Ontario), Denmark, Sweden, Spain (Catalonia and Valencia) ...
(Date:4/23/2014)... American Society for Radiation Oncology (ASTRO) has issued ... Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline," ... in the treatment of endometrial cancer. The guideline,s ... issue of Practical Radiation Oncology (PRO), ... full-length guideline is available as an open-access article ...
(Date:4/23/2014)... of the gastro-intestinal tract has long been considered to ... the Sahlgrenska Academy have used refined microscopic techniques that ... surface of the gastro-intestinal tract is only as large ... , The digestive tract, which passes from the mouth ... a length of about 5 meters in a normal ...
(Date:4/23/2014)... the potential health benefits of probiotics, antioxidants and other ... And the chemical industry is getting in on the ... deter growth, so the industry is responding with clinical ... cover story in Chemical & Engineering News ... Society. , Melody M. Bomgardner, a senior editor at ...
Breaking Medicine News(10 mins):Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... , WASHINGTON , Jan. 29 In today,s ... Bipartisan Policy Center,s (BPC) plan for reforming health care, entitled: ... as a bipartisan health care proposal that is worthy of ... plan, which was developed by former U.S. Senate Majority Leaders ...
... more likely to strike whites than blacks, researchers find , ... its kind finds that Parkinson,s disease in the United States ... whites and Hispanics are twice as likely to develop the ... an analysis of data from 36 million Medicare recipients, are ...
... The Minnesota Medical Association Board of Trustees decided Saturday ... Assistance Medical Care (GAMC) program, but not if such efforts include ... not cover the cost of providing care. , The Board also ... programs. The MMA sent a letter to lawmakers this week. , ...
... New collaboration leverages Joslin,s deep clinical and research expertise and ... BOSTON , Jan. 29 Joslin.org ... Center, the world,s preeminent diabetes research and clinical care organization, and ... with diabetes, today announced a new online partnership. dLife will ...
... quite some time, the "Holy Grail" in medical imaging has ... death as a means to intervene early in diseases and ... researchers at the University of Notre Dame and the Washington ... synthetic probe to target dead and dying cells in mammary ...
... Both ... symptoms of autism with a Biomedical alternative. , ... (PRWEB) January 29, 2010 -- Autism-supplements.com, a Lyndhurst New ... Jenny McCarthy and Jim Carrey’s autism organization, to help raise money and public awareness ...
Cached Medicine News:Health News:President Obama Highlights Bipartisan Policy Center Health Care Reform Plan in Remarks to House Republicans 2Health News:President Obama Highlights Bipartisan Policy Center Health Care Reform Plan in Remarks to House Republicans 3Health News:Parkinson's More Common in Northeast, Midwest 2Health News:Doctors Tell Lawmakers to Find a New GAMC Fix 2Health News:Joslin Diabetes Center and dLife Form New Online Partnership 2Health News:Joslin Diabetes Center and dLife Form New Online Partnership 3Health News:New paper describes important advance in imaging of cell death 2Health News:Autism-Supplements.com and Generation Rescue Work Together to Raise Money for Biomedical Autism Treatments 2
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
A pocket-sized pulse oximeter. Perfect for the physician's office, emergency medicine, hospitals and clinics, and home health care....
... Cost-effective, portable, continuous, or spot ... with alarms and an internal ... and Sleep Study modes make ... the hospital or clinical environment; ...
... Sleep Hand-Held Pulse Oximeter with built-in ... sleep screening studies in the sleep ... With its easy-to-use, 2-key operation, it ... of SpO 2 , pulse rate ...
Medicine Products: